Results 51 to 60 of about 97,920 (228)

Incidence, Risk Factors and Management of Adverse Events in Contemporary Real‐World Care of Children with Juvenile Idiopathic Arthritis

Arthritis Care &Research, Accepted Article.
Objective We describe the frequency, risk factors, severity, and management of actionable and serious adverse events (AAE and SAE) in children with newly diagnosed Juvenile Idiopathic Arthritis (JIA) in Canada. Methods We enrolled patients within 3 months of JIA diagnosis in the Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) Registry,
Bashayer Alnuaimi, Roberta A. Berard, Jean‐Philippe Proulx‐Gauthier, Heinrike Schmeling, Michelle Batthish, Gilles Boire, Adam M. Huber, Dax G. Rumsey, Jaime Guzman, Gaëlle Chédeville, The CAPRI registry Investigators   +10 more
wiley   +1 more source

Model‐informed optimal dose selection of golcadomide in combination with R‐CHOP in patients with previously untreated aggressive B‐cell lymphoma

British Journal of Clinical Pharmacology, EarlyView.
Aims Golcadomide is a potential first‐in‐class oral CELMoD™ agent for the treatment of lymphoma. This study aims to develop model‐informed drug development (MIDD) approaches to support optimal dose selection of golcadomide in combination with immunotherapy rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) in alignment with ...
Xirong Zheng, Zhiling Yu, Mark Kaplan, Argyrios Gkasiamis, Akshay Sudhindra, Li Zhu, Manisha Lamba, Fan Wu   +7 more
wiley   +1 more source

Advances in management of low-risk febrile neutropenia

, 2012
To describe and discuss the most recent advances in the management of low-risk febrile neutropenia in children with ...
Teuffel, Oliver, Sung, Lillian, Lillian Sung, Oliver Teuffel, Teuffel, Marc Oliver   +4 more
core   +1 more source

Cefepime exposure in prolonged or intermittent infusion in critically ill children

British Journal of Clinical Pharmacology, EarlyView.
Aims Cefepime is commonly used in critically ill children for whom there is a high between‐subject variability. To reach the therapeutic pharmacokinetic (PK) target in critically ill patients, prolonged infusion of beta‐lactams seems to be the most efficient.
Marc Hobeika, Deborah Hirt, Emmanuelle Bille, Sihem Benaboud, Julie Toubiana, Pierre‐Louis Léger, Jérôme Rambaud, Agathe Béranger, Delphine Callot, Sylvain Renolleau, Jean‐Marc Treluyer, Mehdi Oualha, Noémie de Cacqueray   +12 more
wiley   +1 more source

A case series of necrotizing periodontal diseases in hospitalized patients: What hasn't been said yet?

Clinical Advances in Periodontics, EarlyView.
Abstract Background Necrotizing periodontal diseases (NPDs) are uncommon and severe inflammatory conditions characterized by tissue necrosis, painful ulceration, and rapid clinical progression, frequently associated with systemic immunosuppression. Limited data exist regarding their clinical presentation and management in hospital settings.
Osmaria Letthycia Carvalho Leal, Fernanda Bortolotto, Mariana Cristina Manoel, Gabriela Silveira de Araújo, Ana Carolina Fragoso Motta, Leandro Dorigan de Macedo, Lara Maria Alencar Ramos Innocentini, Joab Cabral Ramos, Isabel Schausltz Pereira Faustino   +8 more
wiley   +1 more source

Occurrence of febrile neutropenia and neutropenia grade on day 8.

, 2019
Occurrence of febrile neutropenia and neutropenia grade on day 8.
Yoshihiko Furuya (6612659)
core   +1 more source

Clinical Outcomes of Gemcitabine Plus Nab‐Paclitaxel‐Based Chemoradiotherapy in a Multidisciplinary Treatment Strategy for Locally Advanced Pancreatic Cancer (NUPAT‐05): A Prospective, Single‐Arm, Phase II Study

International Journal of Cancer, EarlyView.
ABSTRACT Although chemoradiotherapy (CRT) has exhibited activity against locally advanced pancreatic cancer (LAPC), no standard regimen has been established. We previously completed a Phase I trial of CRT with gemcitabine plus nab‐paclitaxel (GnP) and established the recommended dose.
Hironori Yamada, Haruyoshi Tanaka, Suguru Yamada, Hideki Takami, Masamichi Hayashi, Nobuhiko Nakagawa, Keisuke Kurimoto, Yoshikuni Inokawa, Nobuyuki Watanabe, Takuya Ishikawa, Masayuki Okumura, Hiroshi Ogawa, Masahiko Ando, Osamu Maeda, Junpei Yamaguchi, Shinji Naganawa, Hiroki Kawashima, Tsutomu Fujii, Yukihiro Yokoyama, Tomoki Ebata, Mitsuro Kanda   +20 more
wiley   +1 more source

Management of chemotherapy-associated febrile neutropenia [PDF]

, 2009
The development of febrile neutropenia during a course of chemotherapy is not only a life-threatening complication, it can also lead to a decision to reduce chemotherapy intensity in subsequent treatment cycles, thus putting patient outcomes at risk ...
D Cameron, Cameron, D
core   +1 more source

Pediatric Clostridiodes difficile infection with toxic megacolon successfully treated with fecal microbiota transplantation

JPGN Reports, EarlyView.
Abstract The rising incidence of pediatric Clostridioides difficile infection (CDI), particularly in medically complex patients, calls for novel, individualized treatments. While fecal microbiota transplantation (FMT) is well‐described for recurrent CDI, this report describes the first pediatric case of fulminant CDI with toxic megacolon successfully ...
Dana McCarney, Pamela Chen, Jenna Simes, Stacy A. Kahn   +3 more
wiley   +1 more source

Characteristics of 87 episodes of febrile neutropenia.

, 2016
Characteristics of 87 episodes of febrile neutropenia.
Kristina Broliden (60331), Jan Albert (176517), Anna Lindblom (2826830), Samuel Rhedin (110301), Maria Rotzén-Östlund (110314), Thomas Tolfvenstam (60332), Martina Söderman (2838494)   +6 more
core   +1 more source